Therapeutic Index of Targeted Therapies and Conventional Cytotoxics
Grace Dy, MD, from the Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
As the oncology community has learned over time, the idea that the therapeutic index of targeted therapies as a group is much better than cytotoxics may not be entirely true. Certain toxicities such as myelosuppression or hair loss may not be as common in patients treated with targeted therapies.
Clinical Pearls
Targeted therapies have shown that they can affect multiple organs in the body as some drugs inhibit targets found in normal tissues. This causes an entire spectrum of side effects that are difficult to anticipate. Targeted therapies make treatment much more interesting and challenging for a medical oncologist, Dy says.
- The therapeutic index of targeted therapies as a group is not necessarily better than conventional cytotoxics
- The targets of these therapies may be found in normal tissues and therefore affect multiple organs
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
